The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...
A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans.
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...
More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback